CXCL8 and psoriasis: Examples of failures include an anti-CXCL8 antibody produced by Abgenix [163], which did not meet its endpoints in phase II trials for chronic obstructive pulmonary disease and psoriasis, and anti-CCL2 antibodies for rheumatoid arthritis [164] and metastatic prostate cancer [165] which also failed due to lack of efficacy [37].